Patent · US Active

Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38

US10184005B2 · kind B2 · utility

2Cited by
26References
24Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 8, 2015
Grant dateJan 22, 2019
Priority date
Expiry dateOct 8, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/732
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.